Akebia Therapeutics Inc (NASDAQ:AKBA) shares traded 33.73% higher at $2.26 on Wall Street last session.
AKBA stock price is now 12.18% away from the 50-day moving average and 41.53% away from the 200-day moving average. The market capitalization of the company currently stands at $533.88M.
On August 28, 2023, H.C. Wainwright Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $3.75, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Butler John P., CEO and President sold 46,409 shares of the company’s stock on Mar 03 ’25. The stock was sold for $84,928 at an average price of $1.83. Upon completion of the transaction, the CEO and President now directly owns 2,557,921 shares in the company, valued at $5.78 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 03 ’25, SVP, Chief Medical Officer Burke Steven Keith sold 7,144 shares of the business’s stock. A total of $13,074 was realized by selling the stock at an average price of $1.83. This leaves the insider owning 809,090 shares of the company worth $1.83 million. A total of 4.10% of the company’s stock is owned by insiders.
During the past 12 months, Akebia Therapeutics Inc has had a low of $0.80 and a high of $2.48. The fifty day moving average price for AKBA is $2.0147 and a two-hundred day moving average price translates $1.596835 for the stock.
The latest earnings results from Akebia Therapeutics Inc (NASDAQ: AKBA) was released for 2024-12-31. The company reported revenue of $46.5 million for the quarter, compared to $56.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -17.26 percent. For the current quarter, analysts expect AKBA to generate $44.38M in revenue.
